Triple-negative breast cancer refers to breast cancer without expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu (C-erbB-2), and is considered to be an independent It is considered to be an independent clinicopathological type of breast cancer with aggressive and poor prognosis. It is most often seen in young patients, with a large mass and positive local lymph nodes at the time of diagnosis, and with a family history of breast cancer. The local recurrence rate of triple-negative breast cancer is not significantly different from that of non-triple-negative breast cancer patients; however, patients with triple-negative breast cancer have a higher rate of distant metastases, mainly in important organs such as lung and liver metastases. The prognosis of triple-negative breast cancer is poor because of the lack of therapeutic targets compared with other types of breast cancer, and the lack of effective ways of comprehensive treatment except surgery + chemotherapy. The chemotherapy regimen for triple-negative breast cancer should preferably include anthracyclines and paclitaxel drugs. Through clinical observation, it is recommended that patients with triple-negative breast cancer should have more frequent postoperative periodic review and shorter intervals, so that metastases can be detected early and treated promptly.